Bayer closer to netting Schering AG
Executive Summary
Bayer is closer to completing its friendly takeover of Schering AG after Merck KgaA agrees to relinquish its 21.8% share June 14. As of June 13, Bayer reported ownership of 23.36% of Schering shares; Bayer needs a 75% stake to complete the acquisition. Despite dropping its bid in March, Merck had bought Schering stock to bulk up its share (1"The Pink Sheet" March 27, 2006, p. 10). In response, Bayer filed suit in Manhattan federal court June 13, but dropped the complaint after Merck agreed to relinquish its share...
You may also be interested in...
Bayer/Schering’s Complementary Portfolios Include Focus On Oncology
Bayer does not expect to divest any pharmaceutical products following the acquisition of Schering AG, CEO Werner Wenning said March 24 during a briefing outlining the planned merger
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.